Quadrant Capital Group LLC Acquires 9,966 Shares of Johnson & Johnson $JNJ

Key Points

• Quadrant Capital Group LLC boosted its Johnson & Johnson stake by 15.3% in Q3, buying 9,966 shares to hold 75,309 shares valued at about $13.96 million, making JNJ its 27th-largest position (~0.5% of the fund).
• Other large institutional moves included Capital International Investors adding 3.266 million shares (now 3,865,050 shares worth ~$716.7M) and Legal & General holding 19,450,064 shares, with institutions and hedge funds owning roughly 69.55% of JNJ.
• Regulatory catalysts that could drive revenue include FDA approval of TECVAYLI plus DARZALEX FASPRO and an EU label expansion for Akeega in prostate cancer; meanwhile insiders sold about 30,142 shares (~$7.36M) over the last quarter.

Quadrant Capital Group LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 15.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,309 shares of the company's stock after buying an additional 9,966 shares during the quarter. Johnson & Johnson accounts for approximately 0.5% of Quadrant Capital Group LLC's holdings, making the stock its 27th biggest position. Quadrant Capital Group LLC's holdings in Johnson & Johnson were worth $13,964,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Winthrop Capital Management LLC grew its position in Johnson & Johnson by 3.8% in the 3rd quarter. Winthrop Capital Management LLC now owns 8,533 shares of the company's stock worth $1,582,000 after purchasing an additional 309 shares during the period. Capital International Inc. CA bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at $5,989,000. Capital International Investors lifted its holdings in shares of Johnson & Johnson by 545.6% during the 3rd quarter. Capital International Investors now owns 3,865,050 shares of the company's stock valued at $716,657,000 after buying an additional 3,266,354 shares during the period. Legal & General Group Plc boosted its stake in shares of Johnson & Johnson by 2.8% in the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock worth $3,606,431,000 after buying an additional 532,790 shares during the last quarter. Finally, Banque Cantonale Vaudoise grew its holdings in shares of Johnson & Johnson by 1.8% in the third quarter. Banque Cantonale Vaudoise now owns 71,290 shares of the company's stock worth $13,218,000 after acquiring an additional 1,275 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the combination of TECVAYLI (teclistamab‑cqyv) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma, supported by Phase‑3 MajesTEC‑3 data showing improved progression‑free and overall survival — a meaningful commercial and clinical win that can expand J&J’s oncology revenue and shift treatment patterns earlier in the therapy line. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU expanded approval of Akeega to include BRCA‑mutated metastatic hormone‑sensitive prostate cancer — label expansion that can broaden addressable market in oncology and supports incremental sales in EMEA. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Management’s presentation at the Barclays Global Healthcare Conference provides updated commentary on pipeline priorities and commercialization plans — useful for tracking execution but not a discrete catalyst by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/valuation pieces and recent share‑price momentum have revived investor attention — this could sustain trading interest but depends on execution and revenue contribution from recent approvals. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Negative Sentiment: Short interest rose ~20.8% in February to ~25.09M shares (≈1.0% of shares), raising the short‑interest ratio to ~2.5 days — a small bearish signal that can add volatility if sentiment turns.
• Negative Sentiment: Two J&J units agreed to pay about $65M to settle a Tracleer antitrust class action — a modest cash cost relative to J&J’s size but a legal/expense item to note. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Insider Buying and Selling

In related news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 22,623 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares of the company's stock, valued at $6,540,469.77. This represents a 45.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 30,142 shares of company stock valued at $7,360,528. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Bank of America reissued a "neutral" rating on shares of Johnson & Johnson in a report on Monday, March 2nd. Argus boosted their price target on Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a "market perform" rating in a research note on Friday, January 23rd. The Goldman Sachs Group reissued a "buy" rating and issued a $250.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 22nd. Finally, Citigroup boosted their target price on shares of Johnson & Johnson from $232.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $234.87.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $243.75 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a 50-day simple moving average of $229.80 and a two-hundred day simple moving average of $205.27. The firm has a market capitalization of $587.41 billion, a PE ratio of 22.06, a P/E/G ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson's payout ratio is currently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.